Guardant Health (NASDAQ:GH) Director Ian Clark Sells 14,180 Shares

Guardant Health, Inc. (NASDAQ:GH) Director Ian Clark sold 14,180 shares of the firm’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $158.92, for a total value of $2,253,485.60. Following the sale, the director directly owned 2,975 shares in the company, valued at approximately $472,787. This trade represents a 82.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Guardant Health Trading Up 2.1%

Guardant Health stock opened at $163.18 on Thursday. The company has a market capitalization of $21.90 billion, a PE ratio of -46.76 and a beta of 1.60. Guardant Health, Inc. has a 12 month low of $43.66 and a 12 month high of $176.58. The stock has a 50-day moving average price of $145.75 and a two-hundred day moving average price of $114.50.

Institutional Investors Weigh In On Guardant Health

A number of institutional investors have recently modified their holdings of GH. V Square Quantitative Management LLC bought a new position in Guardant Health during the fourth quarter worth $27,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Guardant Health in the 4th quarter worth about $31,000. Elyxium Wealth LLC acquired a new position in shares of Guardant Health in the 4th quarter valued at about $35,000. Parallel Advisors LLC lifted its stake in shares of Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after purchasing an additional 219 shares during the period. Finally, Ascentis Independent Advisors bought a new stake in shares of Guardant Health during the 1st quarter valued at about $38,000. 92.60% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on GH shares. TD Cowen raised their price objective on shares of Guardant Health from $200.00 to $210.00 and gave the company a “buy” rating in a report on Friday, July 31st. BTIG Research lifted their price target on shares of Guardant Health from $190.00 to $195.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Bank of America boosted their price objective on shares of Guardant Health from $135.00 to $190.00 and gave the stock a “buy” rating in a research note on Monday, July 6th. Sanford C. Bernstein increased their price objective on Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, July 2nd. Finally, Mizuho raised their target price on Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Guardant Health has an average rating of “Moderate Buy” and a consensus price target of $183.78.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.